Understanding and calculating steady state pharmacokinetics
Steady state pharmacokinetics can seem abstract and confusing. Read this blog to gain a better…
Ana HenryMarch 5, 2026
Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer
This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…
Danielle PillsburyMarch 4, 2026
ADC first-in-human (FIH) dose selection: Designing FIH studies for success
Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…
CertaraMarch 3, 2026
Embracing model-informed drug discovery: The path to better clinical outcomes
We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…
CertaraFebruary 27, 2026
Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit)
This webinar introduces the Phoenix IVIVC Toolkit, showing how to perform BE analysis and build…
CertaraFebruary 27, 2026
Alternative parameters in NCA using Phoenix WinNonlin
Learn how to enhance formulation evaluation using Phoenix tools to calculate advanced PK parameters beyond…
CertaraFebruary 23, 2026
FAQs: The ICH M15 guideline and what it means for model-informed drug development
Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…
CertaraFebruary 18, 2026
Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)
Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…
CertaraFebruary 13, 2026
